Table 4.
Multivariable competing risks regression for factors associated with IBTR
| Final Margin | ||
| ≤2 mm | Ref | |
| >2 mm | 0.9 (0.2,3.9) | 0.9 |
| Receptor Subtype | ||
| HR+ HER2− | Ref | |
| HR+/− HER2+ | 1.0 (0.1, 8.3) | >0.9 |
| TN | 6.1 (1.1, 34.2) | 0.04 |
| Clinical T Stage | ||
| 1 | Ref | |
| 2 | 1.4 (0.2, 11.2) | 0.8 |
| 3 | 3.6 (0.4, 33.2) | 0.2 |
| 4 | 5.1 (0.5, 48.0) | 0.1 |
| Pathologic T Stage | ||
| ypT0 | Ref | |
| ypTis | 12.8 (1.3, 129) | 0.03 |
| ypT1 | 3.1 (0.4, 24.1) | 0.3 |
| ypT2 | 12.0 (1.5, 99.0) | 0.02 |
| ypT3 | NA* (NA) | -- |
*
counts too low for hazard ratio estimation
IBTR: ipsilateral breast tumor recurrence; CI: confidence interval; HR: hormone receptor; TN: triple negative; Ref: reference